echocardiographic evidence for valvular toxicity of benfluorex a double-blind randomised trial in patients with type 2 diabetes mellitus超声心动图的证据瓣膜毒性benfluorex双盲随机试验的2型糖尿病患者.pdfVIP

Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus ` 1 1 ´ 2 1 3 Genevieve Derumeaux , Laura Ernande , Andre Serusclat , Evelyne Servan , Eric Bruckert , 4 5 6 7 7 8 Hugues Rousset , Stephen Senn , Luc Van Gaal , Brigitte Picandet , Franc¸ois Gavini , Philippe Moulin *, on behalf the REGULATE trial investigators ˆ ˆ 1 Echocardiography Laboratory, Hopital Louis Pradel, Lyon, France, 2 Department of Medical Imaging and Endocrinology, Hopital Louis Pradel, Lyon, France, ˆ ´ ˆ ` ˆ 3 Department of Endocrinology and Metabolism, Hopital Pitie Salpetriere, Batiment Husson Mourier, Paris, France, 4 Internal Medicine, Centre Hospitalier, Pierre Benite, France, 5 Department of Statistics, University of Glasgow, Glasgow, United Kingdom, 6 Department of Diabetology, Metabolism Clinical Nutrition, Faculty of Medicine, ˆ University Hospital Antwerp, Edegem-Antwerp, Belgium, 7 Institut de Recherches Internationales Servier, Courbevoie, France, 8 Endocrinology Department, Hopital Louis Pradel, Hospices Civils de Lyon, University Lyon1, Lyon, France Abstract Objectives: REGULATE trial was designed to compare the efficacy and safety of benfluorex versus pioglitazone in type 2 diabetes mellitus (D